Allogene Therapeutics 3Q Loss/Shr 15c >ALLO
Story updates
09:09:36 PM UTC
SquawkNews
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. NASDAQ:ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today provided corporate updates and reported financi…